A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Inclusion Criteria: * Patients with locally advanced BCC and metastatic BCC * Patients with adequate bone marrow, liver, and renal function Exclusion Criteria: * Patients who had had major surgery within 4 weeks of initiation of study medication * Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes. * Patients with concurrent medical conditions that may interfere or potentially affect the interpretation of the study. * Patients with neuromuscular disorders or are on concurrent treatment with drugs that may cause muscle damage. * Patients who were on concurrent therapy with other anti-neoplastic agents. * Patients who had taken part in an experimental drug within 4 weeks of initiation of study medication. * Pregnant or nursing (lactating) women * Women of child bearing potential unwilling to use 2 forms of highly effective contraception throughout the study and for 3 months after the last treatment * Fertile males not willing to use condoms throughout the study and for 3 months after the last treatment. * Patients who were unwilling or unable to comply with the protocol.